Bortezomib, Low Dose Cyclophosphamide and G-CSF in Promoting Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000021864
- Lead Sponsor
- Ochanomizu Hematology Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 8
Not provided
(1)Patient has hypersensitivity to bortezomib, cyclophosphamide, and G-CSF. (2)Patient has Grade =>2 peripheral neuropathy (3)Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, cardiac amyloidosis (4)Known interstitial Pneumonitis (5)Uncontrolled intercurrent infection (6)Known HBs antigen positive, HCV antibody positive (7)Known HTLV-I antibody positive, HIV antibody positive (8)Female patients who are pregnant and/or breastfeeding. (9)Active gastrointestinal bleeding (10)Serious psychiatric illness (11)A co-morbid condition which, in the view of the investigators, renders the patient at high risk for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Successful mobilization (Single collection:>4x106/kg CD34 positive cell) rate
- Secondary Outcome Measures
Name Time Method